Differentiating Agents in the Expanding HER2-Targeted Arsenal for Metastatic Breast Cancer
- Author
- ReachMD
- Published
- Thu 06 Feb 2025
- Episode Link
- http://reachmd.com/programs/cme/differentiating-agents-in-the-expanding-her2-targeted-arsenal-for-metastatic-breast-cancer/29944/
CME credits: 1.00
Valid until: 18-06-2026
Claim your CME credit at https://reachmd.com/programs/cme/differentiating-agents-in-the-expanding-her2-targeted-arsenal-for-metastatic-breast-cancer/29944/
Valid until: 18-06-2026
Claim your CME credit at https://reachmd.com/programs/cme/differentiating-agents-in-the-expanding-her2-targeted-arsenal-for-metastatic-breast-cancer/29944/
The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review treatment selection and sequencing considerations for these agents.
